Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Layout and formatting updates to the study record page were observed. Core study content like eligibility criteria, outcomes, and enrollment status remains unchanged.
    Difference
    0.1%
    Check dated 2026-03-25T21:00:33.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-18T15:53:37.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Revision tag on the page updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T14:16:32.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page shows a system revision (Revision: v3.4.2) and removal of a prior revision (v3.4.1), plus a site-wide notice about government funding status. These are administrative updates and do not modify trial content or study details; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T02:19:30.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Notice added about government funding lapse affecting data currency; page revision updated to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-04T00:43:39.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Added a Show glossary option and minor metadata label updates (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0), and removed older terms with different capitalization/wording (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T00:13:47.000Z thumbnail image

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.